Clinical trials: Cancer (Solid Tumors)
Advanced Solid Tumors
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors.
- Trial name
- NCT06723964
- Testing
- AP505
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- AP Biosciences Inc.
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Solid Cancers
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
The study consists of two stages. In Stage 1, maximum tolerated dose (MTD) will be determined. In Stage 2, additional patients will be treated at the MTD of GDC-0152.
- Trial name
- NCT00977067
- Testing
- GDC-0152
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Solid Tumor
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
- Trial name
- NCT05357911
- Testing
- AB-106, digoxin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
HER2-Positive Solid Tumors
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated…
- Trial name
- NCT04501770
- Testing
- Chort 1 of M802, Chort 2 of M802, Cohort 3 of M802
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00025129
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Solid Tumor
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with…
- Trial name
- NCT04937153
- Testing
- Acasunlimab, Pembrolizumab
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Genmab
Advanced Solid Tumor
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
- Trial name
- NCT05879822
- Testing
- INCB099280
- Where
- 54 sites in Brazil, China and 7 more
- Volunteers
- 73 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumors
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study…
- Trial name
- NCT04058756
- Testing
- PDR001
- Where
- 48 sites in United States, Belgium and 15 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Select Advanced Solid Tumors
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME.
- Trial name
- NCT04262466
- Testing
- Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy
- Where
- 76 sites in United States, Australia and 15 more
- Volunteers
- 410 people
- Sponsor
- Immunocore Ltd
Neoplasms
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression.
- Trial name
- NCT02659631
- Testing
- PF-06671008
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Advanced Solid Tumors
A Phase I Study of LEE011 in Asian Patients
This study will evaluate safety and tolerability to estimate the MTD and/or recommended dose for expansion.
- Trial name
- NCT01898845
- Testing
- LEE011
- Where
- 2 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
A Study of ERY974 in Patient With Advanced Solid Tumors
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity.
- Trial name
- NCT02748837
- Testing
- ERY974
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- Chugai Pharmaceutical
Locally Advanced/Metastatic Solid Tumors
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants…
- Trial name
- NCT06414460
- Testing
- ISM3412
- Where
- 10 sites in United States, China
- Volunteers
- 146 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Cancer, Metastatic Solid Malignancies
Consolidation Therapy in Patients With Metastatic Solid Malignancies
This study evaluates the effectiveness of Tumor Associated Peptide Antigens (TAPA) pulsed dendritic cell injections as a potential consolidation therapy for patients with metastatic solid malignancies (SM).
- Trial name
- NCT02705703
- Testing
- TAPA-pulsed DC vaccine
- Sponsor
- Kiromic BioPharma Inc.
Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with…
- Trial name
- NCT06069570
- Testing
- KB-GDT-01
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Kiromic BioPharma Inc.
Advanced Solid Tumors
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.
- Trial name
- NCT07093970
- Testing
- MRG006A
- Where
- 2 sites in China
- Volunteers
- 343 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Solid Tumor, Breast Cancer
A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects
This is an open-label, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Gastrointestinal Cancer
- Trial name
- NCT02742935
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.